A protocol pre-specified interim overall survival (OS) analysis of GEMSTONE-302: A phase 3 study of sugemalimab (suge) versus placebo plus platinum-based chemotherapy (chemo) as first-line (1L) treatment for patients (pts) with metastatic non–small cell lung cancer (NSCLC).

培美曲塞 卡铂 医学 临床终点 安慰剂 内科学 中期分析 中止 肿瘤科 无进展生存期 化疗 代理终结点 临床试验 顺铂 病理 替代医学
作者
Caicun Zhou,Ziping Wang,Meili Sun,Lejie Cao,Zhiyong Ma,Rong Wu,Yan Yu,Wenxiu Yao,Si Sun,Jianhua Chen,Wu Zhuang,Jiuwei Cui,Xueqin Chen,You Lu,Chunhong Hu,Jingru Wang,Rumei Chen,Mengmeng Qin,Hao Chen,Jason Yang
出处
期刊:Journal of Clinical Oncology [Lippincott Williams & Wilkins]
卷期号:40 (16_suppl): 9027-9027 被引量:6
标识
DOI:10.1200/jco.2022.40.16_suppl.9027
摘要

9027 Background: GEMSTONE-302, a randomized, double-blind, phase 3 study, previously met its primary endpoint and demonstrated statistically significant and clinically meaningful prolongation of progression-free survival (PFS) with suge+chemo vs placebo+chemo as a 1L treatment in pts with metastatic NSCLC. PFS benefit was observed in both squamous (sq) and non-squamous (nsq) NSCLC, regardless of PD-L1 expression levels. Here we report the data from a protocol pre-specified interim OS analysis. Methods: Pts with systemic treatment-naïve stage IV NSCLC, measurable disease per RECIST v1.1, ECOG PS 0-1, and no known EGFR, ALK, ROS1 and RET alterations were randomized 2:1 to receive suge (1200 mg, IV) or placebo plus chemo (sq-NSCLC: carboplatin+paclitaxel; nsq-NSCLC: carboplatin+pemetrexed) every 3 weeks for up to 4 cycles, followed by maintenance therapy (sq-NSCLC: suge/placebo; nsq-NSCLC: suge/placebo+pemetrexed) for up to 35 cycles. The primary endpoint was investigator assessed PFS (INV-PFS). Key secondary endpoints included OS, INV-PFS in pts with tumor PD-L1 expression ≥1%, and ORR. Pts in the placebo group could cross over to receive suge monotherapy upon disease progression. Results: As of 22 Nov 2021, among all 479 enrolled pts, 51 (15.9%) and 7 (4.4%), respectively, remained on treatment with suge+chemo or placebo+chemo. The median follow-up was 25.4 and 24.9 months, respectively. Following treatment discontinuation, 17.8% and 43.4% of the pts, respectively, received cross-over suge or other non-study anti-PD-(L)1-containing therapies. Median OS was 25.4 months in suge+chemo group vs 16.9 months in placebo+chemo group (HR = 0.65 [95%CI, 0.50-0.84], p = 0.0008), and 2-year OS rate was 51.7% vs 35.6%. OS benefits were observed across all subgroups including different tumor histologies (sq: HR = 0.56; nsq: HR = 0.72) and PD-L1 expression levels (≥1%: HR = 0.64; < 1%: HR = 0.66). In the intent-to-treat population, median PFS was 9.0 months with suge+chemo vs 4.9 months with placebo+chemo (HR = 0.49 [0.40-0.61]), and 2-year PFS rate was 20.8% vs 7.3%. In pts with PD-L1≥1%, the median PFS was 10.9 vs 4.9 months (HR = 0.48 [0.36-0.63], p < 0.0001). ORR was 63.4% vs 40.3% (p < 0.0001). Among pts with baseline brain metastases, suge+chemo improved their OS (HR = 0.45) and intracranial INV-PFS (post-hoc analysis, HR = 0.33) vs placebo+chemo. Safety profile was consistent with previously reported results. Conclusions: Suge plus chemo demonstrated statistically significant and clinically meaningful OS improvement compared with placebo plus chemo, irrespective of tumor histology or PD-L1 expression levels, in pts with newly diagnosed metastatic NSCLC, offering a new 1L treatment option for this group of pts. Clinical trial information: NCT03789604.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
彭于晏发布了新的文献求助10
刚刚
洛玥发布了新的文献求助10
刚刚
1秒前
1秒前
zrf发布了新的文献求助100
2秒前
李健的粉丝团团长的应助被mjq采纳,获得10
2秒前
NexusExplorer的应助被ECCE采纳,获得10
2秒前
牧木完成签到,获得积分10
2秒前
影逐光发布了新的文献求助10
2秒前
3秒前
传奇3的应助被hahage采纳,获得50
3秒前
精明梦柏完成签到,获得积分10
3秒前
3秒前
核桃发布了新的文献求助10
3秒前
勇猛的小qin完成签到 ,获得积分10
3秒前
冷酷的问梅完成签到,获得积分10
4秒前
科研通AI2S的应助被curry采纳,获得10
4秒前
自信谷冬发布了新的文献求助10
4秒前
宁灭龙发布了新的文献求助10
4秒前
5秒前
明理鸿完成签到,获得积分10
5秒前
如何让人发布了新的文献求助10
5秒前
6秒前
6秒前
顾矜的应助被wang采纳,获得30
6秒前
6秒前
6秒前
7秒前
mm完成签到,获得积分10
7秒前
8秒前
jiangjiang完成签到,获得积分10
8秒前
yyyyyy完成签到,获得积分10
8秒前
8秒前
科研通AI2S的应助被牧木采纳,获得10
8秒前
lz完成签到,获得积分10
8秒前
WYH发布了新的文献求助10
8秒前
田好好发布了新的文献求助10
9秒前
123完成签到 ,获得积分10
9秒前
123发布了新的文献求助10
9秒前
小蘑菇的应助被谨慎的秋烟采纳,获得10
9秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1500
John McDowells Bildungstheorie 800
Analyses de reconnaissances de dettes passées devant les échevins d'Ypres (1249-1291) 600
Handbook of Pharmaceutical Excipients. 9th ed 400
Synthesis, Application and Future Perspectives of Smart Nano-materials - Part 1 400
Breaking the World 300
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8155737
求助须知:如何正确求助?哪些是违规求助? 9552018
关于积分的说明 21707687
捐赠科研通 7744923
什么是DOI,文献DOI怎么找? 3426177
关于科研通互助平台的介绍 2551229
邀请新用户注册赠送积分活动 2469949